NCT06510582

Chronic Subdural Hematoma Treatment With Intra-Arterial Bevacizumab Injection

Chronic Subdural Hematoma Treatment With Avastin® (Bevacizumab) Intra-Arterial Injection: A Non-Randomized, Open-Label Phase 1/2 Clinical Trial

• Status: Recruiting
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 140 (estimated)
• Sponsor: The Cooper Health System · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The goal of this clinical trial is to test whether infusing bevacizumab into the middle meningeal arteries can be used to treat chronic subdural hematomas (cSDH). The main questions it aims to answer are: * Is bevacizumab infusion safe in cSDH patients? * Is bevacizumab infusion effective in treating cSDH?

Conditions

• Chronic Subdural Hematoma

Interventions

Type	Name	Description
DRUG	Bevacizumab 2 mg/kg	Single 2mg/kg dose of bevacizumab to treat unilateral cSDH
DRUG	Bevacizumab 4 mg/kg	Two 2mg/kg doses (cumulatively 4mg/kg) of bevacizumab to treat bilateral cSDH

Timeline

• Start date: 2024-06-17
• Primary completion: 2028-06-01
• Completion: 2028-06-01
• First posted: 2024-07-19
• Last updated: 2025-07-01

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study